EyePoint Pharmaceuticals, Inc.
Clinical trials sponsored by EyePoint Pharmaceuticals, Inc., explained in plain language.
Develops ophthalmic therapies for eye diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug could slash injection frequency for wet AMD patients Results expected Oct 2026 (estimated) May already have reported ↗ 🚀 Make-or-break
-
New eye drug could slash injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or the standard drug aflibercept. The goal is to see if EYP-1901 can maintain or…
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug could mean fewer shots for Diabetes-Related vision loss
Disease control OngoingThis study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug aims to cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 people with wet AMD will receive either EYP-1901 or standard aflibercept injections over 2 years. The main goal is to see …
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New eye drug could cut injection frequency for Diabetes-Related vision loss
Disease control OngoingThis phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …
Phase 3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC